JP2010508360A - Ｃ型肝炎ウイルスの阻害剤 - Google Patents

Ｃ型肝炎ウイルスの阻害剤 Download PDF

Info

Publication number: JP2010508360A
Authority: JP; Japan
Prior art keywords: alkyl; cycloalkyl; mmol; hcv; compound
Prior art date: 2006-11-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2009535434A

Other languages

English (en)

Japanese (ja)

Other versions

JP2010508360A5 (2

Inventor

スタンリー・ダンドレア

ジジェン・バーバラ・ジェン

ポール・マイケル・スコーラ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-01

Filing date

2007-10-31

Publication date

2010-03-18

2007-10-31 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2010-03-18 Publication of JP2010508360A publication Critical patent/JP2010508360A/ja

2010-10-28 Publication of JP2010508360A5 publication Critical patent/JP2010508360A5/ja

Status Withdrawn legal-status Critical Current

Links

0 CCC([C@]1C[C@](CCCC(**CC[C@@](CNC)*C)=O)C1)=* Chemical compound CCC([C@]1C[C@](CCCC(**CC[C@@](CNC)*C)=O)C1)=* 0.000 description 12
NHZWCYNEHQXFQE-UHFFFAOYSA-N C=[O]c1nc(-c2ccccc2)ccn1 Chemical compound C=[O]c1nc(-c2ccccc2)ccn1 NHZWCYNEHQXFQE-UHFFFAOYSA-N 0.000 description 1
VNMCEYCCKZZGHQ-LWKPJOBUSA-N CC(C)(C)OC(N(CC(C1)Oc2c3[o]nc(C)c3nc(-c(cc3)ccc3F)c2)[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC(C1)Oc2c3[o]nc(C)c3nc(-c(cc3)ccc3F)c2)[C@@H]1C(O)=O)=O VNMCEYCCKZZGHQ-LWKPJOBUSA-N 0.000 description 1
ZQEBQGAAWMOMAI-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CCC1)C1C(O)=O)=O ZQEBQGAAWMOMAI-UHFFFAOYSA-N 0.000 description 1
LFKDJXLFVYVEFG-UHFFFAOYSA-N CC(C)(C)OC(N)=O Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
ZITSMHNTPLVPSI-YIDMKWSQSA-N CC(C)(C)OC(N[C@@H](CCCCC/C=C\[C@H](C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CCCCC/C=C\[C@H](C1)[C@]1(C(O)=O)NC([C@H]1N2CCC1)=O)C2=O)=O ZITSMHNTPLVPSI-YIDMKWSQSA-N 0.000 description 1
VRODMOMYNFZSFC-MRLMVZBDSA-N CC(C)(C)OC(N[C@@H](CCCOC/C=C\C(C1)[C@H]1C(NS(C1CC1)(=O)=O)=O)C(N(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(N)=O)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CCCOC/C=C\C(C1)[C@H]1C(NS(C1CC1)(=O)=O)=O)C(N(C[C@@H](C1)OCc2ccccc2)[C@@H]1C(N)=O)=O)=O VRODMOMYNFZSFC-MRLMVZBDSA-N 0.000 description 1
RLXAOJXQUJXJQV-ZDUSSCGKSA-N CC(C)(C)OC(N[C@@H](CN(CCCC=C)C1CC1)C(O)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](CN(CCCC=C)C1CC1)C(O)=O)=O RLXAOJXQUJXJQV-ZDUSSCGKSA-N 0.000 description 1
UDSUJFMZPGOEQG-VIFPVBQESA-N CC(C)(OC(N[C@](C1)(C(O)=O)C1=C)=O)S Chemical compound CC(C)(OC(N[C@](C1)(C(O)=O)C1=C)=O)S UDSUJFMZPGOEQG-VIFPVBQESA-N 0.000 description 1
WXUCBUGUUVYAAN-YNODCEANSA-N COC(C(C1)NC[C@@H]1Oc1c(cc(c(OC)c2)OC)c2nc(C2CC2)n1)=O Chemical compound COC(C(C1)NC[C@@H]1Oc1c(cc(c(OC)c2)OC)c2nc(C2CC2)n1)=O WXUCBUGUUVYAAN-YNODCEANSA-N 0.000 description 1
FXINDYXFGNANSA-UHFFFAOYSA-N COCC1(CC1)S(N)(=O)=O Chemical compound COCC1(CC1)S(N)(=O)=O FXINDYXFGNANSA-UHFFFAOYSA-N 0.000 description 1
MTBCEAHKLOSWCG-UHFFFAOYSA-L C[Sn+](CCCCS)(N)(O)O Chemical compound C[Sn+](CCCCS)(N)(O)O MTBCEAHKLOSWCG-UHFFFAOYSA-L 0.000 description 1
VFPFMOXMHVQFNR-UHFFFAOYSA-N Clc1c(cc[s]2)c2ccn1 Chemical compound Clc1c(cc[s]2)c2ccn1 VFPFMOXMHVQFNR-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP2009535434A 2006-11-01 2007-10-31 Ｃ型肝炎ウイルスの阻害剤 Withdrawn JP2010508360A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86383706P	2006-11-01	2006-11-01
PCT/US2007/083120 WO2008057871A2 (en)	2006-11-01	2007-10-31	Inhibitors of hepatitis c virus

Publications (2)

Publication Number	Publication Date
JP2010508360A true JP2010508360A (ja)	2010-03-18
JP2010508360A5 JP2010508360A5 (2)	2010-10-28

Family

ID=39218835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009535434A Withdrawn JP2010508360A (ja)	2006-11-01	2007-10-31	Ｃ型肝炎ウイルスの阻害剤

Country Status (6)

Country	Link
US (1)	US8343477B2 (2)
EP (1)	EP2089385B1 (2)
JP (1)	JP2010508360A (2)
CN (1)	CN101646667A (2)
NO (1)	NO20091704L (2)
WO (1)	WO2008057871A2 (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
RU2008152171A (ru) *	2006-07-05	2010-08-10	Интермьюн, Инк. (Us)	Новые ингибиторы вирусной репликации гепатита с
SG174809A1 (en) *	2007-05-03	2011-10-28	Intermune Inc	Macrocyclic compounds useful as inhibitors of hepatitis c virus
JP2010526834A (ja) *	2007-05-10	2010-08-05	インターミューン・インコーポレーテッド	Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤
WO2009005690A2 (en) *	2007-06-29	2009-01-08	Gilead Sciences, Inc.	Antiviral compounds
ES2437147T3 (es) *	2008-02-04	2014-01-09	Idenix Pharmaceuticals, Inc.	Inhibidores de serina proteasa macrocíclicos
WO2009142842A2 (en) *	2008-04-15	2009-11-26	Intermune, Inc.	Novel macrocyclic inhibitors of hepatitis c virus replication
US8207341B2 (en)	2008-09-04	2012-06-26	Bristol-Myers Squibb Company	Process or synthesizing substituted isoquinolines
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
AR075584A1 (es) *	2009-02-27	2011-04-20	Intermune Inc	COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
TW201040181A (en)	2009-04-08	2010-11-16	Idenix Pharmaceuticals Inc	Macrocyclic serine protease inhibitors
US8936781B2 (en)	2009-05-13	2015-01-20	Enanta Pharmaceuticals, Inc.	Macrocyclic compounds as hepatitis C virus inhibitors
US8232246B2 (en) *	2009-06-30	2012-07-31	Abbott Laboratories	Anti-viral compounds
EP2461811B1 (en)	2009-08-05	2016-04-20	Idenix Pharmaceuticals LLC.	Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
CN102741270B (zh) *	2009-09-28	2015-07-22	英特穆恩公司	C型肝炎病毒复制的环肽抑制剂
US9193740B2 (en) *	2009-10-19	2015-11-24	Enanta Pharmaceuticals, Inc.	Bismacrocyclic compounds as hepatitis C virus inhibitors
CA2822357A1 (en)	2010-12-22	2012-06-28	Abbvie Inc.	Hepatitis c inhibitors and uses thereof
KR20140003521A (ko)	2010-12-30	2014-01-09	이난타 파마슈티칼스, 인코포레이티드	페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
EP2658859A4 (en)	2010-12-30	2014-07-30	Enanta Pharm Inc	MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
AR085352A1 (es)	2011-02-10	2013-09-25	Idenix Pharmaceuticals Inc	Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8691757B2 (en)	2011-06-15	2014-04-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EA025560B1 (ru)	2012-10-19	2017-01-30	Бристол-Майерс Сквибб Компани	Ингибиторы вируса гепатита с
WO2014071007A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
WO2014070964A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2914614B1 (en)	2012-11-05	2017-08-16	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
WO2014137869A1 (en)	2013-03-07	2014-09-12	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
EP3089757A1 (en)	2014-01-03	2016-11-09	AbbVie Inc.	Solid antiviral dosage forms
CN103965286B (zh) *	2014-04-22	2017-11-03	南京安赛莱医药科技有限公司	丙型肝炎病毒（hcv）ns3蛋白酶抑制剂
US10842763B2 (en)	2015-07-31	2020-11-24	The Johns Hopkins University	Methods for cancer and immunotherapy using prodrugs of glutamine analogs
AU2016302940B2 (en)	2015-07-31	2021-02-04	The Johns Hopkins University	Prodrugs of glutamine analogs
CA2994165A1 (en)	2015-07-31	2017-02-09	The Johns Hopkins University	Methods for cancer and immunotherapy using glutamine analogues, including don
CN111566083A (zh)	2017-10-06	2020-08-21	约翰·霍普金斯大学	新的谷氨酰胺拮抗剂及其用途

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0475255A3 (en) *	1990-09-12	1993-04-14	F. Hoffmann-La Roche Ag	Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
AP1019A (en)	1996-10-18	2001-10-16	Vertex Pharma	Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
EP1012180B1 (en)	1997-08-11	2004-12-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor peptide analogues
ES2241157T3 (es)	1997-08-11	2005-10-16	Boehringer Ingelheim (Canada) Ltd.	Peptidos inhibidores de la hepatitis c.
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
AR022061A1 (es)	1998-08-10	2002-09-04	Boehringer Ingelheim Ca Ltd	Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en)	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7244721B2 (en)	2000-07-21	2007-07-17	Schering Corporation	Peptides as NS3-serine protease inhibitors of hepatitis C virus
CN1498224A (zh)	2000-07-21	2004-05-19	��鹫˾	用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
ES2263687T3 (es)	2000-11-20	2006-12-16	Bristol-Myers Squibb Company	Inhibidores tripeptidicos de la hepatitis c.
US6867185B2 (en)	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
CA2369711A1 (en)	2002-01-30	2003-07-30	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en)	2002-02-01	2003-08-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor tri-peptides
CA2369970A1 (en)	2002-02-01	2003-08-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor tri-peptides
US6828301B2 (en)	2002-02-07	2004-12-07	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
US20060199773A1 (en)	2002-05-20	2006-09-07	Sausker Justin B	Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
ES2361011T3 (es)	2002-05-20	2011-06-13	Bristol-Myers Squibb Company	Inhibidores del virus de la hepatitis c.
ATE481106T1 (de)	2002-05-20	2010-10-15	Bristol Myers Squibb Co	Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
DE60324552D1 (en)	2002-05-20	2008-12-18	Bristol Myers Squibb Co	Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
US20040033959A1 (en)	2002-07-19	2004-02-19	Boehringer Ingelheim Pharmaceuticals, Inc.	Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en)	2002-10-25	2005-04-07	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en)	2003-02-07	2009-10-13	Enanta Pharmaceuticals, Inc.	Macrocyclic hepatitis C serine protease inhibitors
CA2515216A1 (en)	2003-02-07	2004-08-26	Enanta Pharmaceuticals, Inc.	Macrocyclic hepatitis c serine protease inhibitors
WO2004101605A1 (en)	2003-03-05	2004-11-25	Boehringer Ingelheim International Gmbh	Hepatitis c inhibiting compounds
DE602004029866D1 (de)	2003-03-05	2010-12-16	Boehringer Ingelheim Pharma	Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
MXPA05010338A (es)	2003-04-02	2005-11-17	Boehringer Ingelheim Int	Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c.
ES2320771T3 (es)	2003-04-16	2009-05-28	Bristol-Myers Squibb Company	Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
CN1788006A (zh)	2003-04-18	2006-06-14	安南塔制药公司	喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂
AU2004240704B9 (en)	2003-05-21	2009-10-22	Boehringer Ingelheim International Gmbh	Hepatitis C inhibitor compounds
WO2004113365A2 (en)	2003-06-05	2004-12-29	Enanta Pharmaceuticals, Inc.	Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en)	2003-07-03	2006-10-24	Enanta Pharmaceuticals, Inc.	Aza-peptide macrocyclic hepatitis C serine protease inhibitors
RS20060197A (sr)	2003-09-22	2008-09-29	Boehringer Ingelheim International Gmbh.,	Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
WO2005037860A2 (en)	2003-10-10	2005-04-28	Vertex Pharmaceuticals Incoporated	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
HRP20130098T1 (hr)	2003-10-14	2013-02-28	F. Hoffmann - La Roche Ag	MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
US7132504B2 (en)	2003-11-12	2006-11-07	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7135462B2 (en)	2003-11-20	2006-11-14	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2007532479A (ja)	2003-11-20	2007-11-15	シェーリング　コーポレイション	Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター
US7309708B2 (en)	2003-11-20	2007-12-18	Birstol-Myers Squibb Company	Hepatitis C virus inhibitors
EP1730167B1 (en)	2004-01-21	2011-01-12	Boehringer Ingelheim International GmbH	Macrocyclic peptides active against the hepatitis c virus
PL1713822T3 (pl)	2004-01-30	2010-08-31	Medivir Ab	Inhibitory proteazy serynowej HCV NS-3
BRPI0509467A (pt)	2004-03-30	2007-09-11	Intermune Inc	compostos macrocìclicos como inibidores de replicação viral
WO2006016930A2 (en)	2004-05-14	2006-02-16	Intermune, Inc.	Methods for treating hcv infection
EP1753775B1 (en)	2004-05-25	2012-12-26	Boehringer Ingelheim International GmbH	Process for preparing acyclic hcv protease inhibitors
EP1763531A4 (en)	2004-06-28	2009-07-01	Boehringer Ingelheim Int	ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES
RS51974B (sr)	2004-07-16	2012-02-29	Gilead Sciences Inc.	Antivirusna jedinjenja
JP4914355B2 (ja)	2004-07-20	2012-04-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎インヒビターペプチド類似体
UY29016A1 (es)	2004-07-20	2006-02-24	Boehringer Ingelheim Int	Analogos de dipeptidos inhibidores de la hepatitis c
CA2577812A1 (en)	2004-08-27	2006-03-09	Schering Corporation	Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
US7375218B2 (en)	2004-09-17	2008-05-20	Boehringer Ingelheim International Gmbh	Process for preparing macrocyclic HCV protease inhibitors
WO2007001406A2 (en)	2004-10-05	2007-01-04	Chiron Corporation	Aryl-containing macrocyclic compounds
MX2007004783A (es)	2004-10-21	2007-05-11	Pfizer	Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
US7323447B2 (en)	2005-02-08	2008-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2006220708B9 (en)	2005-03-08	2013-01-17	Boehringer Ingelheim International Gmbh	Process for preparing macrocyclic compounds
CA2606195C (en)	2005-05-02	2015-03-31	Merck And Co., Inc.	Hcv ns3 protease inhibitors
US7592336B2 (en)	2005-05-10	2009-09-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
NZ563365A (en)	2005-06-02	2011-02-25	Schering Corp	Combination of HCV protease inhibitors with a surfactant
US20060276404A1 (en)	2005-06-02	2006-12-07	Anima Ghosal	Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
NZ563361A (en)	2005-06-02	2011-02-25	Schering Corp	HCV protease inhibitors in combination with food
US20070004635A1 (en)	2005-06-02	2007-01-04	Schering Corporation	Method of treating interferon non-responders using HCV protease inhibitor
US20070021351A1 (en)	2005-06-02	2007-01-25	Schering Corporation	Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
WO2006130554A2 (en)	2005-06-02	2006-12-07	Schering Corporation	Methods of treating hepatitis c virus
WO2006130552A2 (en)	2005-06-02	2006-12-07	Schering Corporation	Methods of treating hepatitis c virus
US20060276405A1 (en)	2005-06-02	2006-12-07	Schering Corporation	Methods for treating hepatitis C
US20060281689A1 (en)	2005-06-02	2006-12-14	Schering Corporation	Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20060287248A1 (en)	2005-06-02	2006-12-21	Schering Corporation	Asymmetric dosing methods
JP2008545748A (ja)	2005-06-02	2008-12-18	シェーリングコーポレイション	Ｃ型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物
US7601686B2 (en)	2005-07-11	2009-10-13	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TWI389908B (zh)	2005-07-14	2013-03-21	Gilead Sciences Inc	抗病毒化合物類
TW200738742A (en)	2005-07-14	2007-10-16	Gilead Sciences Inc	Antiviral compounds
AR057456A1 (es)	2005-07-20	2007-12-05	Merck & Co Inc	Inhibidores de la proteasa ns3 del vhc
EP1910378B1 (en)	2005-07-20	2012-06-20	Boehringer Ingelheim International GmbH	Hepatitis c inhibitor peptide analogs
AU2006276246B2 (en)	2005-07-25	2012-09-27	Intermune, Inc.	Novel macrocyclic inhibitors of hepatitis C virus replication
TW200745061A (en)	2005-07-29	2007-12-16	Tibotec Pharm Ltd	Macrocylic inhibitors of hepatitis C virus
TWI375670B (en)	2005-07-29	2012-11-01	Tibotec Pharm Ltd	Macrocylic inhibitors of hepatitis c virus
BRPI0614620A2 (pt)	2005-07-29	2011-04-12	Tibotec Pharm Ltd	compostos inibidores macrocìclicos do vìrus da hepatite c, uso dos mesmos, processo para preparar os referidos compostos, combinação e composição farmacêutica
PE20070210A1 (es)	2005-07-29	2007-04-16	Tibotec Pharm Ltd	Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101273042B (zh)	2005-07-29	2013-11-06	泰博特克药品有限公司	丙型肝炎病毒的大环抑制剂
US8012939B2 (en)	2005-07-29	2011-09-06	Tibotec Pharmaceuticals Ltd. Co	Macrocyclic inhibitors of hepatitis C virus
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070343A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Inhibidores macrociclicos del virus de la hepatitis c
RU2419619C2 (ru)	2005-07-29	2011-05-27	Медивир Аб	Макроциклические ингибиторы вируса гепатита с
RU2436787C2 (ru)	2005-07-29	2011-12-20	Тиботек Фармасьютикалз Лтд.	Макроциклические ингибиторы вируса гепатита с
JO2768B1 (en)	2005-07-29	2014-03-15	تيبوتيك فارماسيوتيكالز ليمتد	Large cyclic inhibitors of hepatitis C virus
NZ565269A (en)	2005-08-01	2010-03-26	Merck & Co Inc	Macrocyclic peptides as HCV NS3 protease inhibitors
EP1915382A2 (en)	2005-08-01	2008-04-30	Phenomix Corporation	Hepatitis c serine protease inhibitors and uses therefor
AR055395A1 (es)	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
ES2356776T3 (es)	2005-10-11	2011-04-13	Intermune, Inc.	Compuestos y métodos para inhibir la replicación del virus de la hepatitis.
US7772183B2 (en)	2005-10-12	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7741281B2 (en)	2005-11-03	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2007082131A1 (en)	2006-01-09	2007-07-19	Bristol-Myers Squibb Company	Process for the preparation of hydroxy substituted heterocycles
JP2009528353A (ja)	2006-03-03	2009-08-06	シェーリングコーポレイション	Ｈｃｖのプロテアーゼ阻害剤およびｉｒｅｓ阻害剤の医薬的組み合わせ
GB0609492D0 (en)	2006-05-15	2006-06-21	Angeletti P Ist Richerche Bio	Therapeutic agents
US20070281884A1 (en)	2006-06-06	2007-12-06	Ying Sun	Macrocyclic oximyl hepatitis C protease inhibitors
US7635683B2 (en)	2006-08-04	2009-12-22	Enanta Pharmaceuticals, Inc.	Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7582605B2 (en)	2006-08-11	2009-09-01	Enanta Pharmaceuticals, Inc.	Phosphorus-containing hepatitis C serine protease inhibitors
US7605126B2 (en)	2006-08-11	2009-10-20	Enanta Pharmaceuticals, Inc.	Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20080107623A1 (en) *	2006-11-01	2008-05-08	Bristol-Myers Squibb Company	Inhibitors of Hepatitis C Virus
US20080107625A1 (en) *	2006-11-01	2008-05-08	Bristol-Myers Squibb Company	Inhibitors of Hepatitis C Virus

2007
- 2007-10-25 US US11/923,918 patent/US8343477B2/en active Active
- 2007-10-31 WO PCT/US2007/083120 patent/WO2008057871A2/en not_active Ceased
- 2007-10-31 CN CN200780049038A patent/CN101646667A/zh active Pending
- 2007-10-31 EP EP07863696.6A patent/EP2089385B1/en active Active
- 2007-10-31 JP JP2009535434A patent/JP2010508360A/ja not_active Withdrawn
2009
- 2009-04-29 NO NO20091704A patent/NO20091704L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP2089385A2 (en)	2009-08-19
WO2008057871A3 (en)	2008-10-09
US8343477B2 (en)	2013-01-01
EP2089385B1 (en)	2016-01-06
NO20091704L (no)	2009-07-27
US20080107624A1 (en)	2008-05-08
CN101646667A (zh)	2010-02-10
WO2008057871A2 (en)	2008-05-15

Legal Events

Date

Code

Title

Description

2010-09-08

A521

Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100907

2010-09-08

A621

Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621